Successful strategy for product development
Formycon is developing the biosimilars of tomorrow, which are in compliance with the strict requirements for quality, safety and efficacy of the world’s most highly regulated markets
By offering lower-cost drugs, we strive to make powerful new treatment options available to more patients, while at the same time helping to ease the financial burden on healthcare systems.
Formycon is able to carry out all steps of the biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, all the way through to regulatory approval. Our strategy is to license out our biosimilar drug candidates at the stage of phase I clinical testing, or even earlier, to major pharmaceutical or generic drug corporations. At present, the company has four biosimilar candidates in preclinical and clinical testing phases, two of them have already been out-licensed. License partner for FYB201 is Bioeq IP AG, a joint venture of Santo Holding AG and Polpharma Group. License partner for FYB203 is Santo Holding (Deutschland) GmbH.
We will, over the medium term, continue to expand our pipeline so that it is filled with a balanced mix of early-stage and advanced-stage development candidates.
Formycon starts early enough with the development work with the aim to enable a day-one launch of its biosimilars direct after patent expiry of the reference product.
We apply the highest standards to the biosimilar we develop. Our team of scientific experts and qualified staff, spanning all aspects of biosimilar development, ensures that these products fulfil the stringent quality requirements and regulatory approval requirements of the world’s most demanding markets.